| Ticker Details |
Novavax, Inc.
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
|
| IPO Date: |
December 13, 1995 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.39B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.81 | 3.59%
|
| Avg Daily Range (30 D): |
$0.30 | 3.13%
|
| Avg Daily Range (90 D): |
$0.24 | 2.75%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
3.99M |
| Avg Daily Volume (30 D): |
4.28M |
| Avg Daily Volume (90 D): |
4.02M |
| Trade Size |
| Avg Trade Size (Sh.): |
194 |
| Avg Trade Size (Sh.) (30 D): |
118 |
| Avg Trade Size (Sh.) (90 D): |
132 |
| Institutional Trades |
| Total Institutional Trades: |
8,933 |
| Avg Institutional Trade: |
$3.49M |
| Avg Institutional Trade (30 D): |
$2.69M |
| Avg Institutional Trade (90 D): |
$2.23M |
| Avg Institutional Trade Volume: |
.1M |
| Avg Institutional Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.48M |
| Avg Closing Trade (30 D): |
$3.81M |
| Avg Closing Trade (90 D): |
$2.93M |
| Avg Closing Volume: |
232.41K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$2.72
|
$.11
|
$2.72
|
|
Diluted EPS
|
$2.58
|
$.05
|
$2.58
|
|
Revenue
|
$1.12B
|
$147.14M
|
$1.12B
|
|
Gross Profit
|
$1.05B
|
$125.04M
|
$1.05B
|
|
Net Income / Loss
|
$440.3M
|
$17.53M
|
$440.3M
|
|
Operating Income / Loss
|
$452.8M
|
$14.23M
|
$452.8M
|
|
Cost of Revenue
|
$73.04M
|
$22.1M
|
$73.04M
|
|
Net Cash Flow
|
$-289.24M
|
$-27.31M
|
$-289.24M
|
|
PE Ratio
|
3.16
|
|
|
|
|
|
